AU7808098A - Small molecule sulfonamide hair growth compositions and uses - Google Patents
Small molecule sulfonamide hair growth compositions and uses Download PDFInfo
- Publication number
- AU7808098A AU7808098A AU78080/98A AU7808098A AU7808098A AU 7808098 A AU7808098 A AU 7808098A AU 78080/98 A AU78080/98 A AU 78080/98A AU 7808098 A AU7808098 A AU 7808098A AU 7808098 A AU7808098 A AU 7808098A
- Authority
- AU
- Australia
- Prior art keywords
- straight
- branched chain
- alkenyl
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
WO 99/62490 PCT/US98/11253 SMALL MOLECULE SULFONAMIDE HAIR GROWTH COMPOSITIONS AND USES This application is a continuation-in-part of 5 U.s. Patent Application No. 08/869,426, filed on June 4, 1997, the entire contents of which are herein incorporated by reference. BACKGROUND OF THE INVENTION 10 1. Field of Invention This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using low molecular weight, 15 small molecule sulfonamides. 2. Description of Related Art Hair loss occurs in a variety of situations. These situations include male pattern alopecia, 20 alopecia senilis, alopecia areata, diseases accompanied by basic skin lesions or tumors, and systematic disorders such as nutritional disorders and internal secretion disorders. The mechanisms causing hair loss are very complicated, but in some instances 25 can be attributed to aging, genetic disposition, the activation of male hormones, the loss of blood supply to hair follicles, and scalp abnormalities. The immunosuppressant drugs FK506, rapamycin and cyclosporin are well known as potent T-cell specific WO 99/62490 PCT/US98/11253 2 immunosuppressants, and are effective against graft rejection after organ transplantation. It has been reported that topical, but not oral, application of FK506 (Yamamoto et al., J. Invest. Dermatol., 1994, 5 102, 160-164; Jiang et al., J. Invest. Dermatol. 1995, 104, 523-525) and cyclosporin (Iwabuchi et al., J. Dermatol. Sci. 1995, 9, 64-69) stimulates hair growth in a dose-dependent manner. One form of hair loss, alopecia areata, is known to be associated with 10 autoimmune activities; hence, topically administered immunomodulatory compounds are expected to demonstrate efficacy for treating that type of hair loss. The hair growth stimulating effects of FK506 have been the subject of an international patent filing covering 15 FK506 and structures related thereto for hair growth stimulation (Honbo et al., EP 0 423 714 A2) . Honbo et al. discloses the use of relatively large tricyclic compounds, known for their immunosuppressive effects, as hair revitalizing agents. 20 The hair growth and revitalization effects of FK506 and related agents are disclosed in many U.S. patents (Goulet et al., U.S. Patent No. 5,258,389; Luly et al., U.S. Patent No. 5,457,111; Goulet et al., U.S. Patent No. 5,532,248; Goulet et al., U.S. Patent 25 No. 5,189,042; and Ok et al., U.S. Patent No. 5,208,241; Rupprecht et al., U.S. Patent No. 5,284,840; Organ et al., U.S. Patent No. 5,284,877). These patents claim FK506 related compounds. Although WO 99/62490 PCT/US98/11253 3 they do not claim methods of hair revitalization, they disclose the known use of FK506 for effecting hair growth. Similar to FK506 (and the claimed variations in the Honbo et al. patent), the compounds claimed in 5 these patents are relatively large. Further, the cited patents relate to immunomodulatory compounds for use in autoimmune related diseases, for which FK506's efficacy is well known. Other U.S. patents disclose the use of 10 cyclosporin and related compounds for hair revitalization (Hauer et al., U.S. Patent No. 5,342,625; Eberle, U.S. Patent No. 5,284,826; Hewitt et al., U.S. Patent No. 4,996,193). These patents also relate to compounds useful for treating 15 autoimmune diseases and cite the known use of cyclosporin and related immunosuppressive compounds for hair growth. However, immunosuppressive compounds by definition suppress the immune system and also exhibit 20 other toxic side effects. Accordingly, there is a need for non-immunosuppressant, small molecule compounds which are useful as hair revitalizing compounds. Hamilton and Steiner disclose in U.S. Patent No. 25 5,614,547 novel pyrrolidine carboxylate compounds which bind to the immunophilin FKBP12 and stimulate nerve growth, but which lack immunosuppressive effects. Unexpectedly, it has been discovered that WO 99/62490 PCT/US98/11253 4 these non-immunosuppressant compounds promote hair growth with an efficacy similar to FK506. Yet their novel small molecule structure and non-immuno suppressive properties differentiate them from FK506 5 and related immunosuppressive compounds found in the prior art. SUMMARY OF THE INVENTION The present invention relates to a method for 10 treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a small molecule sulfonamide. The present invention further relates to a pharmaceutical composition which comprises: 15 (i) an effective amount of a small molecule sulfonamide for treating alopecia or promoting hair growth in an animal; and (ii) a pharmaceutically acceptable carrier. The small molecule sulfonamides used in the 20 inventive methods and pharmaceutical compositions may be immunosuppressive, but are preferably non immunosuppressive compounds having an affinity for FKBP-type immunophilins, particularly FKBP12. Non immunosuppressive compounds, as their name suggests, 25 do not exert any significant immunosuppressive activity.
WO 99/62490 PCT/US98/11253 5 BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a photograph of mice treated with a vehicle after six weeks. FIG. 1 shows that less than 3% of the shaved area is covered with new hair growth 5 when the vehicle (control) is administered. FIG. 2 is a photograph of mice treated with 10 pM of a related neuroimmunophilin FKBP ligand, GPI 1044, after six weeks. FIG. 2 shows that 90% of the shaved area is covered with new hair growth when GPI 1044 is 10 administered. FIG. 3 is a photograph of mice treated with 10 pM of another related neuroimmunophilin FKBP ligand, GPI 1116, after six weeks. FIG. 3 shows that 90% of the shaved area is covered with new hair growth when GPI 15 1116 is administered. FIG. 4 is a photograph of mice treated with 3 pM of a third related neuroimmunophilin FKBP ligand, GPI 1102, after six weeks. FIG. 3 shows that 90% of the shaved area is covered with new hair growth when GPI 20 1102 is administered. FIG. 5 is a bar graph plotting the hair growth scores of unshaven animals and shaven animals treated with a vehicle, GPI 1044 (1 pM, 3 pM and 10 AM), GPI 1116 (1 AM and 10 pM), and GPI 1102 (1 AM and 3 AM). 25 FIG. 6 is a bar graph depicting the relative hair growth indices for C57 Black 6 mice treated with a vehicle, FK506, and related neuroimmunophilin FKBP ligands 14 days after treatment with each identified WO 99/62490 PCT/US98/11253 6 compound. Figure 6 demonstrates the remarkable early hair growth promoted by neuroimmunophilin FKBP ligands. 5 DETAILED DESCRIPTION OF THE INVENTION Definitions "Alopecia" refers to deficient hair growth and partial or complete loss of hair, including without limitation androgenic alopecia (male pattern 10 baldness), toxic alopecia, alopecia senilis, alopecia areata, alopecia pelada and trichotillomania. Alopecia results when the pilar cycle is disturbed. The most frequent phenomenon is a shortening of the hair growth or anagen phase due to cessation of cell 15 proliferation. This results in an early onset of the catagen phase, and consequently a large number of hairs in the telogen phase during which the follicles are detached from the dermal papillae, and the hairs fall out. Alopecia has a number of etiologies, 20 including genetic factors, aging, local and systemic diseases, febrile conditions, mental stresses, hormonal problems, and secondary effects of drugs. "GPI 1044" refers to the compound 25 NO 0 O0 D 0 Li WO 99/62490 PCTIUS98/11253 7 wherein B is 3-Phenylpropyl, D is 3-Phenylpropyl, and L is Phenyl. "GPI 1102" refers to 4-phenyl-l- (3-phenylpropyl) butyl 1-(3,3-dimethyl-2-oxopentanoyl)-2 5 piperidinecarboxylate. "GPI 1116" refers to 1-phenethyl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)-2 piperidinecarboxylate. "GPI 1206" refers to a compound of formula 10 N HIN S GPI 1206 15 "Isomers" refer to different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. "Enantiomers" are a pair of 20 stereoisomers that are non-superimposable mirror images of each other. "Diastereoisomers" are stereoisomers which are not mirror images of each other. "Racemic mixture" means a mixture containing equal parts of individual enantiomers. "Non-racemic 25 mixture" is a mixture containing unequal parts of individual enantiomers or stereoisomers. "Pharmaceutically acceptable salt, ester, or solvate" refers to a salt, ester, or solvate of a WO 99/62490 PCT/US98/11253 8 subject compound which possesses the desired pharmacological activity and which is neither biologically nor otherwise undesirable. A salt, ester, or solvate can be formed with inorganic acids 5 such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, 10 glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2 hydroxyethanesulfonate, lactate, maleate, methanesulfonate, naphthylate, 2 -naphthalenesulfonate, nicotinate, oxalate, sulfate, thiocyanate, tosylate 15 and undecanoate. Examples of base salts, esters, or solvates include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine 20 salts; N-methyl-D-glucamine; and salts with amino acids, such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, 25 bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; aralkyl WO 99/62490 PCT/US98/11253 9 halides, such as benzyl and phenethyl bromides; and others. Water or oil-soluble or dispersible products are thereby obtained. "Pilar cycle" refers to the life cycle of hair 5 follicles, and includes three phases: (1) the anagen phase, the period of active hair growth which, insofar as scalp hair is concerned, lasts about three to five years; (2) the catagen phase, the period when growth 10 stops and the follicle atrophies which, insofar as scalp hair is concerned, lasts about one to two weeks; and (3) the telogen phase, the rest period when hair progressively separates and finally falls 15 out which, insofar as scalp hair is concerned, lasts about three to four months. Normally 80 to 90 percent of the follicles are in the anagen phase, less than 1 percent being in the catagen phase, and the rest being in the telogen phase. In 20 the telogen phase, hair is uniform in diameter with a slightly bulbous, non-pigmented root. By contrast, in the anagen phase, hair has a large colored bulb at its root. "Promoting hair growth" refers to maintaining, 25 inducing, stimulating, accelerating, or revitalizing the germination of hair. "Treating alopecia" refers to: (i) preventing alopecia in an animal which may be WO 99/62490 PCT/US98/11253 10 predisposed to alopecia; and/or (ii) inhibiting, retarding or reducing alopecia; and/or (iii) promoting hair growth; and/or 5 (iv) prolonging the anagen phase of the hair cycle; and/or (v) converting vellus hair to growth as terminal hair. Terminal hair is coarse, pigmented, long hair in which the bulb of the hair follicle is seated deep 10 in the dermis. Vellus hair, on the other hand, is fine, thin, non-pigmented short hair in which the hair bulb is located superficially in the dermis. As alopecia progresses, the hairs change from the terminal to the vellus type. 15 Methods of the Present Invention The present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal 20 an effective amount of a small molecule sulfonamide. The inventive method is particularly useful for treating male pattern alopecia, alopecia senilis, alopecia areata, alopecia resulting from skin lesions or tumors, alopecia resulting from cancer therapy such 25 as chemotherapy and radiation, and alopecia resulting from systematic disorders such as nutritional disorders and internal secretion disorders.
WO 99/62490 PCT/US98/11253 11 Pharmaceutical Compositions of the Present Invention The present invention also relates to a pharma ceutical composition comprising: (i) an effective amount of a small molecule 5 sulfonamide; and (ii) a pharmaceutically acceptable carrier. SMALL MOLECULE SULFONAMIDES The sulfonamides used in the methods and 10 pharmaceutical compositions of the present invention are low molecular weight, small molecule compounds having an affinity for FKBP-type immunophilins, such as FKBP12. When a sulfonamide binds to an FKBP-type immunophilin, it has been found to inhibit the prolyl 15 peptidyl cis-trans isomerase, or rotamase, activity of the binding protein. Unexpectedly, the compounds have also been found to stimulate hair growth. These rotamase inhibiting compounds are non-immuno suppressive. Examples of useful compounds are set 20 forth below. FORMULA I An exemplary small molecule sulfonamide is a compound of Formula I 25 K B J A 2 N n D
SO
2 O
E
WO 99/62490 PCT/US98/11253 12 or a pharmaceutically acceptable salt thereof, wherein: A is CH 2 , 0, NH, or N- (CI-C 4 alkyl); B and D are independently Ar, hydrogen, C 1
-C
6 5 straight or branched chain alkyl, or C 2 -C, straight or branched chain alkenyl, wherein said alkyl or alkenyl is unsubstituted or substituted with C5-C 7 cycloalkyl,
C
5 -C, cycloalkenyl or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted 10 with one or two heteroatom(s) independently selected from the group consisting of 0, S, SO, and SO 2 in chemically reasonable substitution patterns, or 15 T Q wherein Q is hydrogen, Cl-C6 straight or 20 branched chain alkyl, or C 2
-C
6 straight or branched chain alkenyl; and T is Ar or C 5 -C, cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from 25 the group consisting of hydrogen, hydroxy, 0- (C 1
-C
4 alkyl), 0- (C 2
-C
4 alkenyl), and carbonyl; provided that both B and D are not hydrogen; WO 99/62490 PCT/US98/11253 13 Ar is selected from the group consisting of phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, monocyclic and bicyclic heterocyclic ring systems with 5 individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of 10 hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, C 1
-C
6 straight or branched chain alkyl, C 2 -C6 straight or branched chain alkenyl, O- (C 1 C 4 straight or branched chain alkyl) , 0- (C 2
-C
4 straight or branched chain alkenyl), 0-benzyl, 0-phenyl, 1,2 15 methylenedioxy, amino, carboxyl, and phenyl; E is C 1
-C
6 straight or branched chain alkyl, C 2
-C
6 straight or branched chain alkenyl, C 5 -C, cycloalkyl,
C
5 -C, cycloalkenyl substituted with C 1
-C
4 straight or branched chain alkyl or C 2
-C
4 straight or branched 20 chain alkenyl, (C 2
-C
4 alkyl or C 2
-C
4 alkenyl) -Ar, or Ar; J is hydrogen, C 1 or C 2 alkyl, or benzyl; K is C 1 C 4 straight or branched chain alkyl, benzyl, or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is 25 substituted with 0, S, SO, or SO 2 ; n is 0 to 3; and the stereochemistry at carbon positions 1 and 2 is R or S.
WO 99/62490 PCT/US98/11253 14 FORMULA II In a preferred embodiment of Formula I, J and K are taken together and the small molecule sulfonamide is a compound of Formula II 5 B (m D ()n O I 10 N I A 0
SO
2 15 or a pharmaceutically acceptable salt thereof, wherein: n is 1 or 2; and m is 0 or 1. In a more preferred embodiment, B is selected 20 from the group consisting of hydrogen, benzyl, 2 phenylethyl, and 3-phenylpropyl; D is selected from the group consisting of phenyl, 3-phenylpropyl, 3-phenoxyphenyl, and 4 phenoxyphenyl; and 25 E is selected from the group consisting of phenyl, 4-methylphenyl, 4-methoxyphenyl, 2-thienyl, 2,4,6-triisopropylphenyl, 4-fluorophenyl, 3 methoxyphenyl, 2-methoxyphenyl, 3, 5-dimethoxyphenyl, WO 99/62490 PCT/US98/11253 15 3,4, 5-trimethoxyphenyl, methyl, 1-naphthyl, 8 quinolyl, 1-(5-N,N-dimethylamino)-naphthyl, 4 iodophenyl, 2,4,6-trimethylphenyl, benzyl, 4 nitrophenyl, 2-nitrophenyl, 4-chlorophenyl, and E 5 styrenyl. FORMULA III Another exemplary small molecule sulfonamide is a compound of Formula III 10 B (in D 0III 15N O=-S= 0 or a pharmaceutically acceptable salt thereof, 20 wherein: B and D are independently Ar, hydrogen, Cl-C 6 straight or branched chain alkyl, or C 2 -C6 straight or branched chain alkenyl, wherein said alkyl or alkenyl is unsubstituted or substituted with C 5
-C
7 cycloalkyl, 25 C.-C, cycloalkenyl or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of 0, S, SO, and SO 2 in WO 99/62490 PCT/US98/11253 16 chemically reasonable substitution patterns, or T 5 wherein Q is hydrogen, C 1
-C
6 straight or branched chain alkyl, or C 2
-C
6 straight or branched chain alkenyl; and 10 T is Ar or C 5
-C
7 cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from the group consisting of hydrogen, hydroxy, O- (C 1
-C
4 alkyl), O- (C 2
-C
4 alkenyl), and 15 carbonyl; provided that both B and D are not hydrogen; Ar is selected from the group consisting of phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 20 monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) 25 independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, C 1
-C
6 straight or branched chain alkyl, C 2
-C
6 straight or branched chain alkenyl, O- (C 1
-
WO 99/62490 PCT/US98/11253 17
C
4 straight or branched chain alkyl) , 0- (C 2
-C
4 straight or branched chain alkenyl), 0-benzyl, 0-phenyl, 1,2 methylenedioxy, amino, carboxyl, and phenyl; E is C,-C 6 straight or branched chain alkyl, C 2 -C6 5 straight or branched chain alkenyl, C 5
-C
7 cycloalkyl,
C
5 -C, cycloalkenyl substituted with C,-C 4 straight or branched chain alkyl or C 2
-C
4 straight or branched chain alkenyl, (C 2
-C
4 alkyl or C 2
-C
4 alkenyl) -Ar, or Ar; and 10 m is 0 to 3. FORMULA IV A further exemplary small molecule sulfonamide is a compound of Formula IV 15 B ' '-D 0IV 20 N O==S0 0 E or a pharmaceutically acceptable salt thereof, 25 wherein: B and D are independently Ar, hydrogen, C 1 -C. straight or branched chain alkyl, or C 2
-C
6 straight or branched chain alkenyl, wherein said alkyl or alkenyl WO 99/62490 PCT/US98/11253 18 is unsubstituted or substituted with C 5 -C, cycloalkyl, C,-C, cycloalkenyl, or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) 5 independently selected from the group consisting of 0, S, SO, and SO2 in chemically reasonable substitution patterns, or T 10 Q wherein Q is hydrogen, C 1
-C
6 straight or 15 branched chain alkyl, or C 2
-C
6 straight or branched chain alkenyl; and T is Ar or C 5 -C, cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from 20 the group consisting of hydrogen, hydroxy, 0- (C-C 4 alkyl), 0-(C 2
-C
4 alkenyl), and carbonyl; provided that both B and D are not hydrogen; Ar is selected from the group consisting of 25 phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in WO 99/62490 PCTIUS98/11253 19 either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of 5 hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, Cl-C 6 straight or branched chain alkyl, C 2
-C
6 straight or branched chain alkenyl, 0- (C 1 C 4 straight or branched chain alkyl) , 0- (C 2
-C
4 straight or branched chain alkenyl), 0-benzyl, 0-phenyl, 1,2 10 methylenedioxy, amino, carboxyl, and phenyl; E is Ci-C 6 straight or branched chain alkyl, C 2
-C
6 straight or branched chain alkenyl, C 5 -C, cycloalkyl,
C
5
-C
7 cycloalkenyl substituted with Cl-C 4 straight or branched chain alkyl or C 2
-C
4 straight or branched 15 chain alkenyl, (C 2
-C
4 alkyl or C 2
-C
4 alkenyl) -Ar, or Ar; and m is 0 to 3. FORMULA V 20 A further exemplary small molecule sulfonamide is a compound of Formula V K B J'V 1 A 2D 25 0 v S0 0
E
WO 99/62490 PCT/US98/11253 20 or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: V is C, N, or S; J and K, taken together with V and the carbon 5 atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) selected from the group consisting of 0, S, SO, SO 2 , N, NH, and NR; 10 R is either C 1
-C
9 straight or branched chain alkyl, C 2
-C
9 straight or branched chain alkenyl, C 3
-C
9 cycloakyl, C 5
-C
7 cycloalkenyl, or Ari, wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group 15 consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C 1
-C
6 straight or branched chain alkyl, C 2
-C
6 straight or branched chain alkenyl, C 1
-C
4 alkoxy, C 2
-C
4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, 20 alkylamino, aminoalkyl, aminocarboxyl, and Ar 2 ; Ar 1 and Ar 2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 25 1-6 heteroatom(s) independently selected from the group consisting of 0, N, and S; A, B, D, E, and n are as defined in Formula I above.
WO 99/62490 PCT/US98/11253 21 Representative species of Formulas I-V are presented in Table I. TABLE I 5 Compound Structure 1 10 N0 o-1s 0 0 15 4 - p h e n y 1 -b u t y 1 - 1 (benzylsulfonyl)-(2R,S)-2 pipecolinate 20 2 O N O=S=0 0 25 1,5-diphenyl-3-pentyl-N-( toluene-sulfonyl)pipecolate WO 99/62490 PCTIUS98/11253 22 TABLE I (continued) Compound Structure 5 3 O N O=S=0 0 10
CH
3 1,7-diphenyl-4-heptyl-N- (para toluene-sulfonyl) pipecolate 15 N 4 'N O=S=0 0 20 3- (3-pyridyl) -1-propyl- (2S) -N- (a toluenesulfonyl)pyrrolidine-2 carboxylate 25 WO 99/62490 PCT/US98/11253 23 TABLE I (continued) Compound Structure 5 5 0 N 0=6=0 0 10
CH
3 4-phenyl-l- butyl -N- (para-toluene sulfonyl)pipecolate 15 6 0 N 20 O=S=O 0 4-phenyl-1-butyl-N- (benzene sulfonyl)pipecolate 25 WO 99/62490 PCT/US98/11253 24 TABLE I (continued) Compound Structure 5 7 0 N O=S=0 0 10 4-phenyl-l-butyl-N-(a-toluene sulfonyl)pipecolate 15 All the compounds of Formulas I-V possess asymmetric centers and thus can be produced as mixtures of stereoisomers or as individual R- and S stereoisomers. The individual stereoisomers may be obtained by using an optically active starting 20 material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving the compounds of Formulas I-V. It is understood that the compounds of Formulas I-V encompass individual stereoisomers as 25 well as mixtures (racemic and non-racemic) of stereoisomers. Preferably, S-stereoisomers are used in the pharmeceutical compositions and methods of the present invention.
WO 99/62490 PCT/US98/11253 25 Synthesis of Small Molecule Sulfonamides The compounds of Formulas I-V may be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathway depicted 5 below. As described by Scheme I, amino acids 1 protected by suitable blocking groups P on the amino acid nitrogen may be reacted with alcohols ROH to generate esters 2. After removal of the protecting group, the free amine 3 may be reacted with various 10 sulfonyl chlorides 4 to provide final products 5 in good to excellent yield. SCHEME I
(CH
2 )n
(CH
2 )n 15 OH R-OH O-R Deprotect N Coupling Method N 1 0 P 0 12 C r-(CH 2 ) n o=S=0 (CH2)n 20 0-R 40 " -R Et3NCH2C12 0 0=s~o 0 3 5 25 Affinity for FKBP12 The compounds used in the inventive methods and pharmaceutical compositions have an affinity for the FK506 binding protein, particularly FKBP12. The WO 99/62490 PCT/US98/11253 26 inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity. 5 K. Test Procedure Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the compounds used in the inventive methods and pharmaceutical compositions can be evaluated by known methods described in the 10 literature (Harding et al., Nature, 1989, 341:758-760; Holt et al. J. Am. Chem. Soc., 115:9923-9938). These values are obtained as apparent Ki's and are presented for representative compounds in TABLE II. The cis-trans isomerization of an alanine-proline 15 bond in a model substrate, N-succinyl-Ala-Ala-Pro-Phe p-nitroanilide, is monitored spectrophotometrically in a chymotrypsin-coupled assay, which releases para nitroanilide from the trans form of the substrate. The inhibition of this reaction caused by the addition 20 of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent Ki values. In a plastic cuvette are added 950 mL of ice cold 25 assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl) , 10 mL of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 mL of test compound at various WO 99/62490 PCTIUS98/11253 27 concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 mL of substrate (succinyl -Ala- Phe - Pro- Phe-para-nitroanilide, 5 mg/mL in 2.35 mM LiCl in trifluoroethanol). 5 The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files. 10 WO 99/62490 PCT/US98/11253 28 TABLE II In Vitro Test Results - Formulas I-V Compound Ki (nM) 5 ON = 72 10 4-phenyl-1-butyl-1- (benzylsulfonyl) (2R,S) -2-pipecolinate (1) 15 34 (N 20 1, 5-diphenyl-3-pentyl-N- (a-toluenesulfonyl) pipecolate (2) WO 99/62490 PCT/US98/11253 29 TABLE II (continued) In Vitro Test Results - Formulas I-V Compound Kj (nM) 5 N O107 O=S=0 0 10
CH
3 1,7-diphenyl-4-heptyl-N-(para-toluene sulfonyl)pipecolate (3) 15 N 20 O=S=0 0 3-(3-pyridyl)-1-propyl-(2S)-N-(a-toluene 25 sulfonyl) pyrrolidine-2-carboxylate (4) WO 99/62490 PCT/US98/11253 30 TABLE II (continued) In Vitro Test Results - Formulas I-V Compound K 1 (nM) 5 504 N O=S=0 0 10
CH
3 15 4-phenyl-1-butyl-N-(para-toluenesulfonyl) pipecolate (5) 470 20 N O=S=O 0 25 4-phenyl-1-butyl-N-(benzenesulfonyl)pipecolate (6) WO 99/62490 PCT/US98/11253 31 TABLE II (continued) In Vitro Test Results - Formulas I-V Compound Ki (iM) 5 127 0USzz0 0 10 4-phenyl-l-butyl-N-(a-toluenesulfonyl) pipecolate (7) 15 Route of Administration To effectively treat alopecia or promote hair growth, the compounds used in the inventive methods and pharmaceutical compositions must readily affect 20 the targeted areas. For these purposes, the compounds are preferably administered topically to the skin. For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, 25 for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the compounds can be formulated into WO 99/62490 PCT/US98/11253 32 suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester 5 wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. Other routes of administration known in the pharmaceutical art are also contemplated by this invention. 10 Dosage Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with 15 preferred levels of about 0.1 mg to about 1,000 mg. The specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex 20 and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, in vitro dosage-effect results provide useful guidance on the proper doses 25 for patient administration. Studies in animal models are also helpful. The considerations for determining the proper dose levels are well known in the art.
WO 99/62490 PCT/US98/11253 33 The compounds can be administered with other hair revitalizing agents. Specific dose levels for the other hair revitalizing agents will depend upon the factors previously stated and the effectiveness of the 5 drug combination. EXAMPLES The following examples are illustrative of the present invention and are not intended to be 10 limitations thereon. Unless otherwise indicated, all percentages are based upon 100% by weight of the final composition. Example 1 15 Synthesis of 3- (3-Pyridyl) -1-propyl (28) -N- (a toluenesulfonyl)pyrrolidine-2-carboxylate (4) 3-(3-Pyridyl)-l-propyl N-(tert-butyloxy carbonvl)pyrrolidine-2-carboxylate A mixture of N-(tert-butyloxycarbonyl)-(S) 20 proline (6.0 g; 28 mmol), 3-(3-pyridyl)-l-propanol (5.80 g; 41.8 mmol) , dicyclohexylcarbodiimide (9.20 g; 44.48 mmol), camphorsulfonic acid (21.60 g; 9.26 mmol) , and 4-dimethylaminopyridine (1.12 g; 9.26 mmol) in dry methylene chloride (200 mL) was stirred 25 overnight. The reaction mixture was filtered through Celite, concentrated, and purified on a silica gel column eluting with 40% ethyl acetate in hexane to obtain 5.0 g of the product as a clear oil (53%) . 'H WO 99/62490 PCT/US98/11253 34 NMR (300 MHz, CDC1 3 ) 6 1.42 (s, 9H) ; 1.43-1.95 (m, 6H); 2.68 (m, 2H) ; 3.46-3.52 (m, 2H); 4.11-4.22 (m, 2H); 4.33 (m, 1H) ; 7.17-7.24 (m, 1H); 7.47 (m, 1H); 8.43 (s, 2H). 5 3-(3-Pyridyl) -1-propyl pyrrolidine-2-carboxylate A solution of 3-(3-pyridyl)-1-propyl N-(tert butyloxycarbonyl)pyrrolidine-2-carboxylate (3.0 g; 8.9 mmol) in methylene chloride (40 mL) and trifluoroacetic acid (8 mL) was stirred at room 10 temperature for three hours. Saturated potassium carbonate was added until the pH was basic, and the reaction mixture was extracted with methylene chloride (3x) . The combined organic extracts were dried and concentrated to yield 1.60 g (77%) of the free amine 15 as a thick oil. 1H NMR (300 MHz, CDCl 3 ) 6 1.71-2.09 (m, 6H); 2.63 (m, 2H); 2.86 (m, 1H); 2.94 (m, 1H); 3.71 (m, 1H); 4.11 (m, 2H); 7.18 (m, 1H); 7.45 (m, 1H) ; 8.41 (m, 2H) . 3-(3-Pyridyl)-1-propyl (2S)-N-(a-toluene 20 sulfonyl)pyrrolidine-2-carboxylate (4) A solution of 3- (3-Pyridyl) -1-propyl pyrrolidine 2-carboxylate (200 mg; 0.9 mmol) and a-toluenesulfonyl chloride (160 mg; 0.9 mmol) in methylene chloride (20 mL) was treated with triethylamine (90 mg; 0.9 mmol) 25 and stirred for 2 hours at room temperature. The reaction mixture was filtered to remove solids and applied directly to a silica gel column, eluting with 50% ethyl acetate in hexane, to obtain 150 mg (43%) of WO 99/62490 PCTIUS98/11253 35 Compound 4 (Table I) as a clear oil. 'H NMR (300 MHz, CDCl 3 ) : 5 1.81-1.85 (m, 2H) ; 1.95-2.02 (m, 3H) ; 2.10 2.25 (m, 1H) ; 2.69-2.74 (t, 2H) ; 2.85-2.97 (m, 1H); 3.24-3.27 (m, 1H); 4.16-4.20 (m, 2H); 4.29 (d, 1H); 5 4.34 (m, 1H) ; 4.45 (d, 1H); 7.20-7.25 (m, 1H) ; 7.35 (m, 3H) ; 7.49-7.52 (m, 3H); 8.46 (s, 2H) . Analysis calculated for C 2 0
H
2
,N
2 0 3 S: C, 61.83; H, 6.23; N, 7.21. Found: C, 61.59; H, 6.24; N, 7.17. 10 Example 2 Synthesis of 4-Phenyl-1-butyl 1- (a-tolylsulfonyl) 2-pipecolinate (7) Methyl 1-(a-tolylsulfonyl)-2-pipecolinate To a solution of methyl pipecolinate 15 hydrochloride (1.79 g; 10 mmol) and triethylamine (1.01 g; 10 mmol) in dry methylene chloride (20 mL) was added a-toluenesulfonyl chloride (1.9 g; 10 mmol). The resulting mixture was stirred at room temperature overnight and then concentrated in vacuo. The crude 20 residue was purified on a silica gel column, eluting with ethyl acetate, to provide 2.20 g (74%) of the product was an oil which solidified upon standing. 'H NMR (CDCl 3 , 300 MHz) : 6 1.26-1.71 (m, 5H); 2.15 (d, 1H, j = 14.4); 3.17 (dt, 1H); 3.45 (d, 1H, j = 12.6); 25 3.78 (s, 3H); 4.28 (s, 2H); 4.58 (m, 1H); 7.26-7.48 (m, 5H). N-(a-tolylsulfonyl)-2-pipecolic acid Methyl 1- (a-tolylsulfonyl) -2-pipecolinate (2.0 g; WO 99/62490 PCT/US98/11253 36 6.72 mmol) was dissolved in ethanol (25 mL) and treated with 20 mL of 1 N lithium hydroxide. The mixture was stirred for 2 hours at room temperature, and then diluted with ethyl acetate (200 mL) and made 5 acidic (pH 2) with 1 N HCL. The organic layer was washed with brine, dried over magnesium sulfate, and concentrated to obtain 1.90 g (100%) of the acid as a white solid. 4-Phenyl-1-butyl 1-(a-tolylsulfonyl)-2-pipecolinate 10 (7) A solution of N-(u-tolylsulfonyl)-2-pipecolic acid (400 mg; 1.41 mmol) , dicyclohexylcarbodiimide (312 mg; 1.5 mmol) , dimethylaminopyridine (7 mg) and 4-phenyl-l-butanol (240 mg; 1.60 mmol) in 100 mL of 15 methylene chloride was stirred overnight at room temperature. The mixture was filtered through Celite, concentrated, and purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 380 mg (48%) of Compound 7 (Table I) as a clear oil. 20 1H NMR (CDCl 3 , 300 MHz) 6 1.10-1.69 (m, 5H) ; 1.70 (tt, 4H, j = 6.1, 6.6); 2.15 (m, 1H); 2.66 (t, 2H, j = 6.6); 3.16 (m, 1H); 3.45 (m, 1H); 4.19 (t, 2H, J = 6.1); 4.28 (s, 2H); 4.58 (m, 1H); 7.18-7.47 (m, 10H). Analysis calculated for C 23
H
29
NO
4 S: C, 66.48; H, 7.03; 25 N, 3.37. Found: C, 66.34; H, 7.06; N, 3.41.
WO 99/62490 PCT/US98/11253 37 Example 3 Synthesis of 1,5-Diphenyl-3-pentyl (N-(a toluenesulfonyl)pipecolate (2) 3-Phenyl-1-propanal 5 Oxalyl chloride (2.90 g; 2.29 mmol) in methylene chloride (50 mL), cooled to -78 0 C, was treated with dimethylsulf oxide (3.4 mL) in 10 mL of methylene chloride. After stirring for 5 minutes, 3-phenyl-1 propanol (2.72 g; 20 mmol) in 20 mL of methylene 10 chloride was added, and the resulting mixture was stirred at -78 0 C for 15 minutes, treated with 14 mL of triethylamine, stirred an additional 15 minutes, and poured into 100 mL of water. The layers were separated, the organic phase was dried and 15 concentrated, and the crude residue was purified on a silica gel column, eluting with 10% ethyl acetate in hexane, to obtain 1.27 g (47%) of the aldehyde as a clear oil. 'H NMR (300 MHz, CDCl 3 ) : 6 2.80 (m, 2H); 2.98 (m, 2H); 7.27 (m, 5H); 9.81 (s, 1H). 20 1,5-Diphenyl-3-pentanol A solution of 2- (bromoethyl)benzene (1.73 g; 9.33 mmol) in diethylether (10 mL) was added to a stirred slurry of magnesium turnings (250 mg; 10.18 mmol) in 5 mL of ether. The reaction was initiated with a heat 25 gun, and after the addition was complete the mixture was heated on an oil bath for 30 minutes. 3-Phenyl-1 propanal (1.25 g; 9.33 mmol) was added in 10 mL of ether, and reflux was continued for 1 hour. The WO 99/62490 PCTIUS98/11253 38 reaction was cooled and quenched with saturated ammonium chloride, extracted into 2x ethyl acetate, and the combined organic portions were dried and concentrated. Chromatographic purification on a 5 silica gel column (10% ethyl acetate in hexane) delivered 1.42 g (63%) of the diphenyl alcohol. 'H NMR (300 MHz, CDCl 3 ): 6 1.84 (m, 4H); 2.61-2.76 (m,4H); 3.65 (m, 1H); 7.19-7.29 (m, 10H). 1,5-Diphenyl-3-pentyl N- (a-toluenesulfonyl)pipecolate 10 (2 A mixture of N- (a-tolylsulfonyl) -2-pipecolic acid (380 mg; 1.34 mmol), 1,5-diphenyl-3-pentanol (485 mg; 2.01 mmol) , dicyclohexylcarbodiimide (445 mg; 2.15 mmol), camphorsulfonic acid (105 mg; 0.45 mmol) and 15 dimethylaminopyridine (55 mg; 0.45 mmol) in 20 mL of methylene chloride was stirred overnight at room temperature. The mixture was filtered through Celite, concentrated, and purified on a silica gel column, eluting with 15% ethyl acetate in hexane, to obtain 20 270 mg (40%) of Compound 2 (Table I) as a clear oil. 'H NMR (CDCl 3 , 300 MHz): 6 0.80 (m, 4H) ; 1.23-1.97 (m, 5H); 2.15 (d, 1H) ; 2.61-2.69 (m, 4H) ; 3.23 (m, 1H) ; 3.44 (dm, 1H); 4.27 (s, 2H); 4.53 (d, 1H, j = 4.5); 5.06 (m, 1H) ; 7.16-7.34 (m, 15H) . Analysis calculated 25 for C 3
,H,,NO
4 S: C, 71.26; H, 6.98; N, 2.77. Found: C, 72.82; H, 7.17; N, 2.53.
WO 99/62490 PCTIUS98/11253 39 Example 4 In Vivo Hair Generation Tests With C57 Black 6 Mice Experiment A: C57 black 6 mice were used to demonstrate the hair revitalizing properties of 5 related neuroimmunophilin FKBP ligands, GPI 1044, GPI 1116, and GPI 1102. C57 black 6 mice, approximately 7 weeks old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to 10 the underlaying dermal layers. The animals were in anagen growth phase, as indicated by the pinkish color of the skin. Referring now to FIGS. 1, 2, 3 and 4, four animals were treated by topical administration with 20% propylene glycol vehicle (FIG. 1), and, for 15 each compound, seven animals were treated by topical administration with, respectively, 10 pM GPI 1044 (FIG. 2), 10 pM GPI 1116 (FIG. 3), or 3 pM GPI 1102 (FIG. 4). The animals were treated with vehicle, GPI 1044, GPI 1116, or GPI 1102 every 48 hours (3 20 applications total over the course of 5 days) and the hair growth was allowed to proceed for 6 weeks. Hair growth was quantitated by the percent of shaved area covered by new hair growth during this time period. FIG. 1 shows that animals treated with vehicle 25 exhibited only a small amount of hair growth in patches or tufts, with less than 3% of the shaved area covered with new growth. In contrast, FIGS. 2, 3 and 4 show that animals treated with the related WO 99/62490 PCT/US98/11253 40 neuroimmunophilin FKBP ligands, 10 pM GPI 1044, 10 pM GPI 1116, and 3 pM GPI 1102, exhibited dramatic hair growth, covering as much as 50% of the shaved area in some animals. FIG. 5 compares the hair growth score 5 of unshaven animals with the hair growth scores of shaven animals treated with a vehicle and with the related neuroimmunophilin FKBP ligands GPI 1044 (1 pM, 3 pM and 10 pM), GPI 1116 (1 pM and 10 pM), and GPI 1102 (1 pM and 3 pM). 10 Experiment B: C57 Black 6 mice were used to demonstrate the hair revitalizing properties of neuroimmunophilin FKBP ligands. C57 Black 6 mice, 55 to 75 days old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all 15 existing hair. Care was taken not to nick or cause abrasion to the underlying dermal layers. The animals were in a anagen growth phase when shaved. Five animals per group were treated by topical administration with a vehicle, FK506, or a 20 neuroimmunophilin FKBP ligand (GPI 1116 or 1206) at a concentration of one micromole per milliliter to the shaved area. The animals were treated three times per week, and hair growth was evaluated 14 days after initiation of treatment. Hair growth was quantitated 25 by the percent of shaved area covered by new hair growth, as scored by a blinded observer, on a scale of 0 (no growth) to five (complete hair regrowth in shaved area).
WO 99/62490 PCTIUS98/11253 41 Figure 6 shows that after 14 days, the animals treated with vehicle exhibited the beginning of growth in small tufts. In contrast, animals treated with a neuroimmunophilin FKBP ligand exhibited dramatic hair 5 growth. Example 5 A lotion comprising the following composition may be prepared. 10 (%) 95% Ethanol 80.0 a small molecule sulfonamide as defined above 10.0 a-Tocopherol acetate 0.01 15 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil purified water 9.0 perfume and dye q.s. 20 Into 95% ethanol are added a small molecule sulfonamide, a-tocopherol acetate, ethylene oxide (40 mole) adducts of hardened castor oil, perfume and a dye. The resulting mixture is stirred and dissolved, and purified water is added to the mixture to obtain 25 a transparent liquid lotion. 5 ml of the lotion may be applied once or twice per day to a site having marked baldness or alopecia.
WO 99/62490 PCT/US98/11253 42 Example 6 A lotion comprising the following composition shown may be prepared. 5 (%) 95% Ethanol 80.0 a small molecule sulfonamide as defined above 0.005 Hinokitol 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 10 castor oil Purified water 19.0 Perfume and dye q.s. Into 95% ethanol are added a small molecule 15 sulfonamide, hinokitol, ethylene oxide (40 mole) adducts of hardened castor oil, perfume, and a dye. The resulting mixture is stirred, and purified water is added to the mixture to obtain a transparent liquid lotion. 20 The lotion may be applied by spraying once to 4 times per day to a site having marked baldness or alopecia.
WO 99/62490 PCT/US98/11253 43 Example 7 An emulsion may be prepared from A phase and B phase having the following compositions. 5 (A phase) (%) Whale wax 0.5 Cetanol 2.0 Petrolatum 5.0 Squalane 10.0 10 Polyoxyethylene (10 mole) monostearate 2.0 Sorbitan monooleate 1.0 a small molecule sulfonamide as defined above 0.01 (B phase) (%) Glycerine 10.0 15 Purified water 69.0 Perfume, dye, and preservative q.s. The A phase and the B phase are respectively heated and melted and maintained at 801c. Both phases 20 are then mixed and cooled under stirring to normal temperature to obtain an emulsion. The emulsion may be applied by spraying once to four times per day to a site having marked baldness or alopecia. 25 WO 99/62490 PCT/US98/11253 44 Example 8 A cream may be prepared from A phase and B phase having the following compositions. 5 (A Phase) (%) Fluid paraffin 5.0 Cetostearyl alcohol 5.5 Petrolatum 5.5 Glycerine monostearate 33.0 10 Polyoxyethylene (20 mole) 2-octyldodecyl 3.0 ether Propylparaben 0.3 (B Phase) (%) a small molecule sulfonamide as defined 0.8 15 above Glycerine 7.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium Hexametaphosphate 0. 005 20 Purified water 44.895 The A phase is heated and melted, and maintained at 70 0 c. The B phase is added into the A phase and the mixture is stirred to obtain an emulsion. The 25 emulsion is then cooled to obtain a cream. The cream may be applied once to 4 times per day to a site having marked baldness or alopecia.
WO 99/62490 PCT/US98/11253 45 Example 9 A liquid comprising the following composition may be prepared. 5 (%) Polyoxyethylene butyl ether 20.0 Ethanol 50.0 a small molecule sulfonamide as defined above 0.001 Propylene glycol 5.0 10 Polyoxyethylene hardened castor oil 0.4 derivative (ethylene oxide 80 mole adducts) Perfume q.s. Purified water q. s. 15 Into ethanol are added polyoxypropylene butyl ether, propylene glycol, polyoxyethylene hardened castor oil, a small molecule sulfonamide, and perfume. The resulting mixture is stirred, and purified water is added to the mixture to obtain a liquid. 20 The liquid may be applied once to 4 times per day to a site having marked baldness or alopecia.
WO 99/62490 PCT/US98/11253 46 Example 10 A shampoo comprising the following composition may be prepared. 5 (%) Sodium laurylsulfate 5.0 Triethanolamine laurylsulfate 5.0 Betaine lauryldimethylaminoacetate 6.0 Ethylene glycol distearate 2.0 10 Polyethylene glycol 5.0 a small molecule sulfonamide as defined above 5.0 Ethanol 2.0 Perfume 0.3 Purified water 69.7 15 Into 69.7 of purified water are added 5.0 g of sodium laurylsulfate, 5.0 g of triethanolamine laurylsulfate, 6.0 g of betaine lauryldimethyl aminoacetate. Then a mixture obtained by adding 5.0 20 g of a small molecule sulfonamide, 5.0 g of polyethylene glycol, and 2.0 g of ethylene glycol distearate to 2.0 g of ethanol, followed by stirring, and 0.3 g of perfume are successively added. The resulting mixture is heated and subsequently cooled to 25 obtain a shampoo. The shampoo may be used on the scalp once or twice per day.
WO 99/62490 PCT/US98/11253 47 Example 11 A patient is suffering from alopecia senilis. A small molecule sulfonamide, or a pharmaceutical composition comprising the same, may be administered 5 to the patient. Increased hair growth is expected to occur following treatment. Example 12 A patient is suffering from male pattern 10 alopecia. A small molecule sulfonamide, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment. 15 Example 13 A patient is suffering from alopecia areata. A small molecule sulfonamide, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to 20 occur following treatment. Example 14 A patient is suffering from hair loss caused by skin lesions. A small molecule sulfonamide, or a 25 pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
WO 99/62490 PCT/US98/11253 48 Example 15 A patient is suffering from hair loss caused by tumors. A small molecule sulfonamide, or a pharmaceutical composition comprising the same, may be 5 administered to the patient. Increased hair growth is expected to occur following treatment. Example 16 A patient is suffering from hair loss caused by 10 a systematic disorder, such as a nutritional disorder or an internal secretion disorder. A small molecule sulfonamide, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur 15 following treatment. Example 17 A patient is suffering from hair loss caused by chemotherapy. A small molecule sulfonamide, or a 20 pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment. Example 18 25 A patient is suffering from hair loss caused by radiation. A small molecule sulfonamide, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is WO 99/62490 PCT/US98/11253 49 expected to occur following treatment. The invention being thus described, it will be obvious that the same may be varied in many ways. 5 Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.
Claims (22)
1. A method for treating alopecia or promoting hair growth in an animal, which comprises 5 administering to said animal an effective amount of a small molecule sulfonamide.
2. The method of claim 1, wherein the small molecule sulfonamide has an affinity for an FKBP-type 10 immunophilin.
3. The method of claim 2, wherein the FKBP-type immunophilin is FKBP-12. 15
4. The method of claim 1, wherein the small molecule sulfonamide is immunosuppressive.
5. The method of claim 1, wherein the small molecule sulfonamide is non-immunosuppressive. 20
6. The method of claim 1, wherein the small molecule sulfonamide is a compound of formula I K B 25 J A 1 2 N n D SO 2 O WO 99/62490 PCT/US98/11253 51 or a pharmaceutically acceptable salt thereof, wherein: A is CH 2 , 0, NH, or N- (C 1 -C 4 alkyl); B and D are independently Ar, hydrogen, Ci-C 6 5 straight or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl, wherein said alkyl or alkenyl is unsubstituted or substituted with C 5 -C 7 cycloalkyl, C 5 -C, cycloalkenyl or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted 10 with one or two heteroatom(s) independently selected from the group consisting of 0, S, SO, and SO 2 in chemically reasonable substitution patterns, or 15 T Q wherein Q is hydrogen, C 1 -C 6 straight or branched chain alkyl, or C 2 -C 6 straight 20 or branched chain alkenyl; and T is Ar or C 5 -C, cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from the group consisting of hydrogen, hydroxy, 25 0- (C 1 -C 4 alkyl), O- (C 2 -C 4 alkenyl), and carbonyl; provided that both B and D are not hydrogen; Ar is selected from the group consisting of WO 99/62490 PCT/US98/11253 52 phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in 5 either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, 10 trifluoromethoxy, Cl-C, straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, O- (Cl C 4 straight or branched chain alkyl) , 0- (C 2 -C 4 straight or branched chain alkenyl), 0-benzyl, 0-phenyl, 1,2 methylenedioxy, amino, carboxyl, and phenyl; 15 E is Cl-C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 5 -C 7 cycloalkyl, C,-C, cycloalkenyl substituted with C 1 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched chain alkenyl, (C 2 -C 4 alkyl or C 2 -C 4 alkenyl) -Ar, or Ar; 20 J is hydrogen, C 1 or C 2 alkyl, or benzyl; K is Cj C 4 straight or branched chain alkyl, benzyl, or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is substituted with 0, S, SO, or SO 2 ; 25 n is 0 to 3; and the stereochemistry at carbon positions 1 and 2 is R or S. WO 99/62490 PCT/US98/11253 53
7. The method of claim 6, wherein J and K are taken together and the compound is represented by formula II 5 B ( m D )n O1 N 10 N O So 2 E or a pharmaceutically acceptable salt thereof, wherein: 15 n is 1 or 2; and m is 0 or 1.
8. The method of claim 6, wherein: B is selected from the group consisting of 20 hydrogen, benzyl, 2-phenylethyl and 3-phenylpropyl; D is selected from the group consisting of phenyl, 3-phenylpropyl, 3-phenoxyphenyl and 4 phenoxyphenyl; and E is selected from the group consisting of 25 phenyl, 4-methylphenyl, 4-methoxyphenyl, 2-thienyl, 2,4,6-triisopropylphenyl, 4-fluorophenyl, 3 methoxyphenyl, 2 -methoxyphenyl, 3,5 -dimethoxyphenyl, 3,4,5-trimethoxyphenyl, methyl, 1-naphthyl, 8- WO 99/62490 PCT/US98/11253 54 quinolyl, 1- (5-N,N-dimethylamino) -naphthyl, 4 iodophenyl, 2,4, 6-trimethylphenyl, benzyl, 4 nitrophenyl, 2-nitrophenyl, 4-chlorophenyl, and E styrenyl. 5
9. The method of claim 1, wherein the small molecule sulfonamide is a compound of formula III B 10 (m D 0II 0 S=::::0 0 15E or a pharmaceutically acceptable salt thereof, wherein: B and D are independently Ar, hydrogen, C 1 -C 6 20 straight or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl, wherein said alkyl or alkenyl is unsubstituted or substituted with C 5 -C 7 cycloalkyl, C,-C, cycloalkenyl or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted 25 with one or two heteroatom(s) independently selected from the group consisting of 0, S, SO, and SO2 in chemically reasonable substitution patterns, or WO 99/62490 PCT/US98/11253 55 T Q 5 wherein Q is hydrogen, Cl-C 6 straight or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl; and 10 T is Ar or C.-C, cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from the group consisting of hydrogen, hydroxy, O- (C 1 -C 4 alkyl) , O- (C 2 -C 4 alkenyl), and 15 carbonyl; provided that both B and D are not hydrogen; Ar is selected from the group consisting of phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 20 monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) 25 independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, Cl-C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, O- (Cl- WO 99/62490 PCT/US98/11253 56 C 4 straight or branched chain alkyl) , 0- (C 2 -C 4 straight or branched chain alkenyl), O-benzyl, 0-phenyl, 1,2 methylenedioxy, amino, carboxyl, and phenyl; E is Cl-C. straight or branched chain alkyl, C 2 -C 6 5 straight or branched chain alkenyl, C 5 -C, cycloalkyl, C 5 -C, cycloalkenyl substituted with C 1 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched chain alkenyl, (C 2 -C 4 alkyl or C 2 -C 4 alkenyl) -Ar, or Ar; and 10 m is 0 to 3.
10. The method of claim 1, wherein the small molecule sulfonamide is a compound of formula IV 15 B ( m D IV N YO 20 = 0 0-S= 0 or a pharmaceutically acceptable salt thereof, wherein: 25 B and D are independently Ar, hydrogen, Cl-C 6 straight or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl, wherein said alkyl or alkenyl is unsubstituted or substituted with C 5 -C, cycloalkyl, WO 99/62490 PCT/US98/11253 57 C 5 -C 7 cycloalkenyl, or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of 0, 5 S, SO, and SO 2 in chemically reasonable substitution patterns, or T 10 wherein Q is hydrogen, C,-C 6 straight or branched chain alkyl, or C 2 -C, straight or branched chain alkenyl; and 15 T is Ar or C 5 -C 7 cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from the group consisting of hydrogen, hydroxy, O- (C 1 -C 4 alkyl), O- (C 2 -C 4 alkenyl), and 20 carbonyl; provided that both B and D are not hydrogen; Ar is selected from the group consisting of phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 25 monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, WO 99/62490 PCTIUS98/11253 58 N, and S; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, C 1 -C 6 straight or branched chain 5 alkyl, C 2 -C 6 straight or branched chain alkenyl, 0- (Cl C 4 straight or branched chain alkyl) , 0- (C 2 -C 4 straight or branched chain alkenyl), O-benzyl, 0-phenyl, 1,2 methylenedioxy, amino, carboxyl, and phenyl; E is Cl-C, straight or branched chain alkyl, C 2 -C, 10 straight or branched chain alkenyl, C.-C, cycloalkyl, C 5 -C, cycloalkenyl substituted with C 1 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched chain alkenyl, (C 2 -C 4 alkyl or C 2 -C 4 alkenyl) -Ar, or Ar; and 15 m is 0 to 3.
11. The method of claim 1, wherein the small molecule sulfonamide is a compound of formula V 20 K B I V v /S02 0 E 25 or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: V is C, N, or S; WO 99/62490 PCT/US98/11253 59 J and K, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more 5 heteroatom(s) selected from the group consisting of 0, S, SO, SO 2 , N, NH, and NR; R is either Cj-C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 3 -C 9 cycloakyl, C 5 -C 7 cycloalkenyl, or Ar, wherein R is 10 either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl, C 2 -C, straight or branched chain 15 alkenyl, Cl-C 4 alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar2; Ar 1 and Ar 2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or 20 heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of 0, N, and S; A, B, D, E, and n are as defined in claim 6 25 above.
12. A pharmaceutical composition which comprises: WO 99/62490 PCT/US98/11253 60 (i) an effective amount of a small molecule sulfonamide for treating alopecia or promoting hair growth in an animal; and (ii) a pharmaceutically acceptable carrier. 5
13. The pharmaceutical composition of claim 12, wherein the small molecule sulfonamide has an affinity for an FKBP-type immunophilin. 10
14. The pharmaceutical composition of claim 13, wherein the FKBP-type immunophilin is FKBP-12.
15. The pharmaceutical composition of claim 12, wherein the small molecule sulfonamide is 15 immunosuppressive.
16. The pharmaceutical composition of claim 12, wherein the small molecule sulfonamide is non immunosuppressive. 20
17. The pharmaceutical composition of claim 12, wherein the small molecule sulfonamide is a compound of formula I 25 K B N A D SO 2 O WO 99/62490 PCT/US98/11253 61 or a pharmaceutically acceptable salt thereof, wherein: A is CH 2 , 0, NH, or N- (Cl-C 4 alkyl); B and D are independently Ar, hydrogen, Cl-C 6 5 straight or branched chain alkyl, or C 2 -C, straight or branched chain alkenyl, wherein said alkyl or alkenyl is unsubstituted or substituted with C 5 -C, cycloalkyl, C,-C, cycloalkenyl or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted 10 with one or two heteroatom(s) independently selected from the group consisting of 0, S, SO, and SO 2 in chemically reasonable substitution patterns, or T 15 wherein Q is hydrogen, Cl-C 6 straight or branched chain alkyl, or C 2 -C 6 straight 20 or branched chain alkenyl; and T is Ar or C 5 -C 7 cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from the group consisting of hydrogen, hydroxy, 25 0- (C 1 -C 4 alkyl), 0- (C 2 -C 4 alkenyl), and carbonyl; provided that both B and D are not hydrogen; WO 99/62490 PCT/US98/11253 62 Ar is selected from the group consisting of phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, monocyclic and bicyclic heterocyclic ring systems with 5 individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of 10 hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, CI-C 6 straight or branched chain alkyl, C 2 -C6 straight or branched chain alkenyl, 0- (Cl C 4 straight or branched chain alkyl) , 0- (C 2 -C 4 straight or branched chain alkenyl), 0-benzyl, 0-phenyl, 1,2 15 methylenedioxy, amino, carboxyl, and phenyl; E is Cl-C, straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 5 -C 7 cycloalkyl, C 5 -C, cycloalkenyl substituted with C 1 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched 20 chain alkenyl, (C 2 -C 4 alkyl or C 2 -C 4 alkenyl) -Ar, or Ar; J is hydrogen, C 1 or C 2 alkyl, or benzyl; K is C 1 C 4 straight or branched chain alkyl, benzyl, or cyclohexylmethyl; or J and K are taken together to form a 5-7 membered heterocyclic ring which is 25 substituted with 0, S, SO, or SO 2 ; n is 0 to 3; and the stereochemistry at carbon positions 1 and 2 is R or S. WO 99/62490 PCT/US98/11253 63
18. The pharmaceutical composition of claim 17, wherein J and K are taken together and the compound is represented by formula II 5 B ( m D N 10 N O SO2 wherein: 15 n is 1 or 2; and m is 0 or 1.
19. The pharmaceutical composition of claim 16, wherein: 20 B is selected from the group consisting of hydrogen, benzyl, 2-phenylethyl and 3-phenylpropyl; D is selected from the group consisting of phenyl, 3-phenylpropyl, 3-phenoxyphenyl and 4 phenoxyphenyl; and 25 E is selected from the group consisting of phenyl, 4-methylphenyl, 4-methoxyphenyl, 2-thienyl, 2,4,6-triisopropylphenyl, 4-fluorophenyl, 3 methoxyphenyl, 2 -methoxyphenyl, 3, 5 - dime thoxyphenyl, WO 99/62490 PCT/US98/11253 64 3,4,5-trimethoxyphenyl, methyl, 1-naphthyl, 8 quinolyl, 1-(5-N,N-dimethylamino)-naphthyl, 4 iodophenyl, 2,4,6-trimethylphenyl, benzyl, 4 nitrophenyl, 2-nitrophenyl, 4-chlorophenyl, and E 5 styrenyl.
20. The pharmaceutical composition of claim 12, wherein the small molecule sulfonamide is a compound of formula III 10 B D 0 III 15 N O=S=0 0 or a pharmaceutically acceptable salt thereof, 20 wherein: B and D are independently Ar, hydrogen, C 1 -C 6 straight or branched chain alkyl, or C 2 -C, straight or branched chain alkenyl, wherein said alkyl or alkenyl is unsubstituted or substituted with C.-C, cycloalkyl, 25 C,-C, cycloalkenyl or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) independently selected from the group consisting of 0, S, SO, and SO 2 in WO 99/62490 PCTIUS98/11253 65 chemically reasonable substitution patterns, or T 5 Q wherein Q is hydrogen, CI-C 6 straight or branched chain alkyl, or C 2 -C, straight or branched chain alkenyl; and 10 T is Ar or Ce-C, cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from the group consisting of hydrogen, hydroxy, O- (C 1 -C 4 alkyl) , O- (C 2 -C 4 alkenyl), and 15 carbonyl; provided that both B and D are not hydrogen; Ar is selected from the group consisting of phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 20 monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) 25 independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, Cl-CE straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, 0- (C,- WO 99/62490 PCT/US98/11253 66 C 4 straight or branched chain alkyl) , 0- (C 2 -C 4 straight or branched chain alkenyl), O-benzyl, 0-phenyl, 1,2 methylenedioxy, amino, carboxyl, and phenyl; E is C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 5 straight or branched chain alkenyl, C.-C, cycloalkyl, C 5 -C 7 cycloalkenyl substituted with C 1 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched chain alkenyl, (C 2 -C 4 alkyl or C 2 -C 4 alkenyl) -Ar, or Ar; and 10 m is 0 to 3.
21. The pharmaceutical composition of claim 12, wherein the small molecule sulfonamide is a compound of formula IV 15 B 0 IIV 20 N 0 J3 0 0 E or a pharmaceutically acceptable salt thereof, 25 wherein: B and D are independently Ar, hydrogen, C 1 -C straight or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl, wherein said alkyl or alkenyl WO 99/62490 PCT/US98/11253 67 is unsubstituted or substituted with C 5 -C 7 cycloalkyl, C,-C 7 cycloalkenyl, or Ar, and wherein one or two carbon atom(s) of said alkyl or alkenyl may be substituted with one or two heteroatom(s) 5 independently selected from the group consisting of 0, S, SO, and SO 2 in chemically reasonable substitution patterns, or T 10 IQ) wherein Q is hydrogen, CI-C 6 straight 15 or branched chain alkyl, or C 2 -C 6 straight or branched chain alkenyl; and T is Ar or C 5 -C 7 cycloalkyl substituted at positions 3 and 4 with one or more substituent(s) independently selected from 20 the group consisting of hydrogen, hydroxy, O- (C 1 -C 4 alkyl) , O- (C 2 -C 4 alkenyl), and carbonyl; provided that both B and D are not hydrogen; Ar is selected from the group consisting of 25 phenyl, 1-napthyl, 2-naphthyl, 2-furyl, 3-furyl, 2 thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which contain in WO 99/62490 PCT/US98/11253 68 either or both rings a total of 1-4 heteroatoms independently selected from the group consisting of 0, N, and S; wherein Ar contains 1-3 substituent(s) independently selected from the group consisting of 5 hydrogen, halo, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, C1-C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, 0-(C 1 C 4 straight or branched chain alkyl), 0- (C 2 -C 4 straight or branched chain alkenyl), 0-benzyl, 0-phenyl, 1,2 10 methylenedioxy, amino, carboxyl, and phenyl; E is Cl-C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 5 -C 7 cycloalkyl, C,-C, cycloalkenyl substituted with C 1 -C 4 straight or branched chain alkyl or C 2 -C 4 straight or branched 15 chain alkenyl, (C 2 -C 4 alkyl or C 2 -C 4 alkenyl) -Ar, or Ar; and m is 0 to 3.
22. The pharmaceutical composition of claim 12, 20 wherein the small molecule sulfonamide is a compound of formula V K B VY A D 25 7 sv 2sB 2 O E WO 99/62490 PCT/US98/11253 69 or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: V is C, N, or S; J and K, taken together with V and the carbon 5 atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) selected from the group consisting of 0, S, SO, SO 2 , N, NH, and NR; 10 R is either C,-C, straight or branched chain alkyl, C 2 -C, straight or branched chain alkenyl, C 3 -C 9 cycloakyl, C 5 -C 7 cycloalkenyl, or Ar, wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group 15 consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, 20 alkylamino, aminoalkyl, aminocarboxyl, and Ar 2 ; Ar 1 and Ar 2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 25 1-6 heteroatom(s) independently selected from the group consisting of 0, N, and S; A, B, D, E, and n are as defined in claim 17 above.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/011253 WO1999062490A1 (en) | 1998-06-03 | 1998-06-03 | Small molecule sulfonamide hair growth compositions and uses |
Publications (2)
Publication Number | Publication Date |
---|---|
AU7808098A true AU7808098A (en) | 1999-12-20 |
AU760663B2 AU760663B2 (en) | 2003-05-22 |
Family
ID=22267205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU78080/98A Ceased AU760663B2 (en) | 1998-06-03 | 1998-06-03 | Small molecule sulfonamide hair growth compositions and uses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1083876A1 (en) |
JP (1) | JP2002516846A (en) |
AU (1) | AU760663B2 (en) |
CA (1) | CA2334395A1 (en) |
WO (1) | WO1999062490A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
BR9914196A (en) * | 1998-09-30 | 2001-06-19 | Procter & Gamble | Hair loss treatment process |
US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
WO2001010838A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent compounds |
AU6388500A (en) * | 1999-08-05 | 2001-03-05 | Procter & Gamble Company, The | Multivalent sulfonamides |
JP5815774B2 (en) * | 2014-02-27 | 2015-11-17 | 一般社団法人グリーンエバー | Hair growth and / or hair growth promoting composition comprising sulfa drug and chitosan drug |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2505114C3 (en) * | 1975-02-07 | 1979-06-13 | Valentin Dr.Med. Koehler | Scalp care products |
WO1988000040A1 (en) * | 1986-07-02 | 1988-01-14 | American Health Products Corporation | Topical hair growing composition and kit |
DE59107440D1 (en) * | 1990-02-19 | 1996-04-04 | Ciba Geigy Ag | Acyl compounds |
GB9200245D0 (en) * | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
AU4966497A (en) * | 1996-11-18 | 1998-06-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same |
-
1998
- 1998-06-03 CA CA002334395A patent/CA2334395A1/en not_active Abandoned
- 1998-06-03 EP EP98926183A patent/EP1083876A1/en not_active Ceased
- 1998-06-03 AU AU78080/98A patent/AU760663B2/en not_active Ceased
- 1998-06-03 JP JP2000551746A patent/JP2002516846A/en active Pending
- 1998-06-03 WO PCT/US1998/011253 patent/WO1999062490A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2334395A1 (en) | 1999-12-09 |
WO1999062490A1 (en) | 1999-12-09 |
EP1083876A1 (en) | 2001-03-21 |
JP2002516846A (en) | 2002-06-11 |
AU760663B2 (en) | 2003-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6191125B1 (en) | Small molecule pipecolic acid derivative hair growth compositions and uses | |
AU770459B2 (en) | Heterocyclic ester and amide hair growth compositions and uses | |
US6187784B1 (en) | Pipecolic acid derivative hair growth compositions and uses | |
AU764032B2 (en) | Small molecule carbamate or urea hair growth compositions and uses | |
AU760663B2 (en) | Small molecule sulfonamide hair growth compositions and uses | |
US6187796B1 (en) | Sulfone hair growth compositions and uses | |
AU761737B2 (en) | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses | |
AU767155B2 (en) | Small molecule pipecolic acid derivative hair growth compositions and uses | |
AU761083B2 (en) | Pipecolic acid derivative hair growth compositions and uses | |
US20020010205A1 (en) | N-linked sulfone of heterocyclic thioester hair growth compositions and uses | |
AU7807998A (en) | N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses | |
MXPA00012011A (en) | Small molecule sulfonamide hair growth compositions and uses | |
MXPA00011877A (en) | Small molecule carbamate or urea hair growth compositions and uses | |
AU8252898A (en) | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses | |
MXPA00011850A (en) | Small molecule pipecolic acid derivative hair growth compositions and uses | |
WO1999062485A1 (en) | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |